Back to Stakeholders

University of California, San Francisco

Also known as: University of California San Francisco, UC San Francisco, UCSF, UCSF Translational Psychedelic Research Program, UCSF TrPR, Psychedelics Division, Neuroscape, UCSF, University of California, San Francisco

CategoriesUniversities and Colleges with Dedicated Psychedelic Research GroupsResearch, Drug Development & Manufacturing

Data updated

7 Trials1 Paper

University of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.

Academic Research

1 papers

Published Papers

1

Trial Involvement

7

Distinct Focus Topics

0

Latest Publication

Mar 18, 2026

Research journey

University of California, San Francisco works on Psilocybin. Here is where that compound’s research stands.

Research journey

332 trials · 753 papers

Full timeline →

Tap any milestone for detail. 1958 to 2026.

Quick Facts

Type
academic
HQ
United States
Website
Visit

Research Landscape

What the registered trials University of California, San Francisco sponsors or participates in look like when you line them up. Counts come from Blossom’s trial records as of July 2026.

What's live right now, and what stopped?

Sourced

Registry status of all 7 University of California, San Francisco trials Blossom tracks. Orange marks trials recruiting or opening.

Recruiting or opening
457%
Underway, not recruiting
229%
Completed
114%
Browse trials →

Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.

Sponsored Trials

2
Active not recruitingI

Comparing the Effects of Psilocin and Psilocybin in Healthy Adults

Start Date
Compounds
Psilocybin
Active not recruitingII

Psilocybin Therapy for Depression in Bipolar II Disorder (BAP)

Start Date
Compounds
Psilocybin

Collaborated Trials

5
RecruitingI

Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

Start Date
Compounds
Psilocybin
RecruitingI

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (PHATHOM)

Start Date
Compounds
Psilocybin
Enrolling by invitationIV

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (REaKT-SD)

Start Date
Compounds
Ketamine, Placebo
RecruitingII

Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC)

Start Date
Compounds
Psilocybin, Ketamine
CompletedII

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

Start Date
Compounds
Psilocybin

Research Papers

1
Paywallmeta

Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions A Systematic Review and Meta-Analysis

This meta-analysis (s=24) found that psychedelic-assisted therapy (s=8) was no more effective than open-label traditional antidepressants for treating major depression, and that, unlike traditional antidepressants (where blinding meaningfully influenced outcomes), PAT trials showed no difference between blinded and open-label conditions, confirming that PAT trials are effectively always unblinded.

Published
Journal
JAMA Psychiatry
Authors
Williams, Z. J., Barnett, H., Szigeti, B.